Ovid Therapeutics Inc. (NASDAQ:OVID)

Ovid Therapeutics Inc. OVID

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 1.06

-7.83 %

$ 75.3 M

Market Cap

-2.59

P/E

1. INTRINSIC VALUE

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H.[ Read More ]

The intrinsic value of one OVID stock under the base case scenario is HIDDEN Compared to the current market price of 1.06 USD, Ovid Therapeutics Inc. is HIDDEN

OVID Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart OVID

FINANCIALS

Annual
Quarterly

392 K REVENUE

Growth Rates

1Year -73.93%

3Years -68.57%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-59.3 M OPERATING INCOME

Growth Rates

1Year -6.72%

3Years 10.04%

5Years -2.29%

7Years -14.82%

10Years 0.00%

-52.3 M NET INCOME

Growth Rates

1Year 3.38%

3Years 13.56%

5Years -0.14%

7Years -12.88%

10Years 0.00%

-45.8 M OPERATING CASH FLOW

Growth Rates

1Year 17.10%

3Years 3.90%

5Years -0.10%

7Years -14.45%

10Years 0.00%

-2.58 M INVESTING CASH FLOW

Growth Rates

1Year 97.06%

3Years -2.42%

5Years 13.61%

7Years -45.27%

10Years 0.00%

30.5 M FINANCING CASH FLOW

Growth Rates

1Year 16802.21%

3Years -13.43%

5Years 154.47%

7Years 200.94%

10Years 0.00%

173 K REVENUE

Growth Rates

1Year -73.93%

3Years -68.57%

5Years 0.00%

7Years 0.00%

10Years 0.00%

-13.2 M OPERATING INCOME

Growth Rates

1Year -6.72%

3Years 10.04%

5Years -2.29%

7Years -14.82%

10Years 0.00%

-14 M NET INCOME

Growth Rates

1Year 3.38%

3Years 13.56%

5Years -0.14%

7Years -12.88%

10Years 0.00%

-15 M OPERATING CASH FLOW

Growth Rates

1Year 17.10%

3Years 3.90%

5Years -0.10%

7Years -14.45%

10Years 0.00%

292 K INVESTING CASH FLOW

Growth Rates

1Year 97.06%

3Years -2.42%

5Years 13.61%

7Years -45.27%

10Years 0.00%

38 K FINANCING CASH FLOW

Growth Rates

1Year 16802.21%

3Years -13.43%

5Years 154.47%

7Years 200.94%

10Years 0.00%

Balance Sheet Decomposition Ovid Therapeutics Inc.

144 M ASSETS
56.2 M LIABILITIES

Current Assets	110 M
Cash & Short-Term Investments	106 M
Receivables	0
Other Current Assets	3.76 M
Non-Current Assets	34.4 M
Long-Term Investments	19.6 M
PP&E	14.7 M
Other Non-Current Assets	210 K

Current Liabilities	11.5 M
Accounts Payable	3.7 M
Short-Term Debt	1.25 M
Other Current Liabilities	6.53 M
Non-Current Liabilities	44.8 M
Long-Term Debt	14.8 M
Other Non-Current Liabilities	30 M

EFFICIENCY

Earnings Waterfall Ovid Therapeutics Inc.

Revenue	392 K
Cost Of Revenue	1.6 M
Gross Profit	-1.2 M
Operating Expenses	59.7 M
Operating Income	-59.3 M
Other Expenses	-6.94 M
Net Income	-52.3 M

RATIOS

-307.61% GROSS MARGIN

Averages

1Year -307.61%

3Years -66.52%

5Years -19.91%

7Years -14.22%

10Years -9.95%

-15134.60% OPERATING MARGIN

Averages

1Year -15134.60%

3Years -6257.14%

5Years -3883.37%

7Years -2773.83%

10Years -1941.68%

-13362.17% NET MARGIN

Averages

1Year -13362.17%

3Years -5574.73%

5Years -3472.80%

7Years -2480.57%

10Years -1736.40%

-59.61% ROE

Averages

1Year -59.61%

3Years -10.05%

5Years -59.96%

7Years -73.06%

10Years -58.56%

-36.34% ROA

Averages

1Year -36.34%

3Years -2.10%

5Years -37.19%

7Years -52.50%

10Years -43.76%

-67.52% ROIC

Averages

1Year -67.52%

3Years -13.00%

5Years -62.18%

7Years -75.37%

10Years -60.21%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Ovid Therapeutics Inc.

Net Income	-52.3 M
Depreciation & Amortization	1.6 M
Capital Expenditures	-137 K
Stock-Based Compensation	7.29 M
Change in Working Capital	2.39 M
Others	-4.07 M
Free Cash Flow	-45.9 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Ovid Therapeutics Inc.

Wall Street analysts predict an average 1-year price target for OVID of $7.33 , with forecasts ranging from a low of $3 to a high of $11 .

OVID Lowest Price Target Wall Street Target

3 USD 183.02%

OVID Average Price Target Wall Street Target

7.33 USD 591.82%

OVID Highest Price Target Wall Street Target

11 USD 937.74%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.

-0.0407 USD

CTMX

Overvalued 104.48%

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

-0.715 USD

SPRO

Overvalued 160.61%

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL).

-11.6 USD

TIL

Overvalued 143.72%

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

0.233 USD

NXTC

Overvalued 82.24%

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.

1.09 USD

ASMB

Overvalued 93.24%

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.

3.18 USD

ACHL

Undervalued 202.40%

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6.

0.177 USD

NUVB

Overvalued 93.29%

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation.

0.265 USD

CNTB

Overvalued 76.11%

6. Ownership

Insider Ownership Ovid Therapeutics Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

50.4 K USD 1

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
8 months ago Mar 18, 2024	Bought 50.4 K USD	LEVIN JEREMY M CEO	+ 18248	2.76 USD
2 years ago Sep 12, 2022	Sell 37.3 K USD	Tardio Jason Chief Operating Officer	- 17344	2.15 USD
3 years ago Jul 14, 2021	Sell 126 K USD	Rakhit Amit President and CMO	- 34017	3.71 USD
4 years ago Aug 28, 2020	Bought 49.6 K USD	LEVIN JEREMY M CEO	+ 8488	5.84 USD
5 years ago Oct 08, 2019	Bought 5 M USD	TAKEDA PHARMACEUTICAL CO LTD 10 percent owner	+ 2000000	2.5 USD
5 years ago Oct 08, 2019	Bought 150 K USD	LEVIN JEREMY M CEO	+ 60000	2.5 USD
5 years ago Feb 26, 2019	Bought 20.2 K USD	Bernstein Karen Director	+ 10000	2.021 USD
5 years ago Feb 22, 2019	Bought 150 K USD	LEVIN JEREMY M CEO	+ 75000	2 USD
6 years ago Aug 14, 2018	Bought 62.3 K USD	Bernstein Karen Director	+ 10000	6.23 USD
6 years ago Aug 14, 2018	Bought 32.4 K USD	WILLIAMS DOUGLAS E Director	+ 5000	6.4883 USD
7 years ago Aug 25, 2017	Bought 110 K USD	LEVIN JEREMY M CEO	+ 15334	7.15 USD

7. News

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago. zacks.com - 4 days ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy. globenewswire.com - 2 months ago

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2 months ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 2 months ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 2 months ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 months ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 months ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 months ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 months ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accesswire.com - 3 months ago

Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago. zacks.com - 3 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024. globenewswire.com - 3 months ago

8. Profile Summary

Ovid Therapeutics Inc. OVID

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 75.3 M

Dividend Yield 0.00%

Description Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Contact 1460 Broadway, New York, NY, 10036 https://www.ovidrx.com

IPO Date May 5, 2017

Employees 25

Officers Dr. Dirk Haasner Senior Vice President of Global Manufacturing & CMC QA Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. Chief Executive Officer & Chairman Ms. Meg Alexander President & Chief Operating Officer Dr. Julia Tsai Ph.D. Senior Vice President of Clinical Development Dr. Toshiya Nishi D.V.M. Head of Epilepsy Research Mr. Tom Parry Vice President of Research and Early Development Mr. Zhong Zhong Ph.D. Chief Scientific Officer Mr. Jeffrey A. Rona Chief Business and Financial Officer

Price Chart OVID

Ovid Therapeutics Inc. OVID

Premium Plan

Unlimited Plan